What is the current market size and future outlook for the metastatic hr+/her2- breast cancer market?
The metastatic HR+/HER2-breast cancer market size has grown rapidly in recent years. It will grow from $9.91 billion in 2024 to $10.92 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising awareness about early diagnosis, increased diagnosis rates, clinical trial successes, pharmaceutical investments and growing adoption of combination therapies.
The metastatic HR+/HER2-breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing adoption of novel therapies, growing use of immunotherapy, expansion into emerging markets, patient advocacy and support programs and focus on quality-of-life improvements. Major trends in the forecast period include next-generation sequencing (NGS), liquid biopsy advancements, biomarker discovery, cell and gene therapy, and monoclonal antibodies (mAbs).
Get Your Free Sample of The Global Metastatic HR+/HER2- Breast Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21220&type=smp
How has the metastatic hr+/her2- breast cancer market evolved, and what factors have shaped its growth?
The increasing hormone replacement therapy (HRT) is expected to propel the growth of the metastatic HR+/HER2- breast cancer market going forward. Hormone replacement therapy (HRT) is a medical treatment used to supplement or replace hormones that are at lower levels in the body, most commonly during menopause or in cases of hormone deficiencies. The increasing hormone replacement therapy (HRT) is due to their effectiveness in improving treatment outcomes, reduced side effects compared to traditional therapies, and advancements in precision medicine. Hormonal replacement therapy (HRT) can support metastatic HR+/HER2- breast cancer by alleviating the symptoms of estrogen deficiency associated with menopause, such as hot flashes and vaginal dryness, without interfering with the effectiveness of endocrine therapies, as it primarily targets hormone imbalances rather than the cancerous cells, ensuring better quality of life for patients undergoing cancer treatment. For instance, in October 2023, according to NHS England, a UK-based government agency, in England during 2022-23, 11 million hormone replacement therapy (HRT) items were prescribed, marking a 47% increase from 2021-22. Therefore, the increasing hormone replacement therapy (HRT) drives the metastatic HR+/HER2- breast cancer market.
What are the major segments of the metastatic hr+/her2- breast cancer market?
The metastatic HR+/HER2- breast cancer market covered in this report is segmented –
1) By Drugs: Paclitaxel, Tamoxifen, Vinblastine, Raloxifene, Docetaxel, Other Drugs
2) By Treatment: Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal Medication
3) By End-User: Hospitals, Clinics, Other End-User
Subsegments:
1) By Paclitaxel: Generic Paclitaxel, Taxol
2) By Tamoxifen: Generic Tamoxifen, Nolvadex
3) By Vinblastine: Generic Vinblastine, Velban
4) By Raloxifene: Generic Raloxifene, Evista
5) By Docetaxel: Generic Docetaxel, Taxotere
6) By Other Drugs: Letrozole, Anastrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report
Which companies dominate the metastatic hr+/her2- breast cancer market?
Major companies operating in the metastatic HR+/HER2- breast cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hengrui Medicine Co Ltd., MacroGenics Inc., Arvinas Inc., Olema Pharmaceuticals Inc., CytomX Therapeutics Inc., G1 Therapeutics Inc., Context Therapeutics Inc., Celcuity Inc., Sermonix Pharmaceuticals Inc., Ambrx Biopharma Inc., Carrick Therapeutics
How will evolving trends contribute to the growth of the metastatic hr+/her2- breast cancer market?
Major companies operating in the metastatic HR+/HER2- breast cancer market are developing combination therapy to expand their indications, market reach, and treatment options. Combination therapy is a treatment approach that involves the simultaneous use of two or more therapeutic agents, which may include chemotherapy, targeted therapy, immunotherapy, hormone therapy, or other modalities, to treat a medical condition more effectively by targeting different pathways, enhancing the overall treatment response, and reducing the likelihood of the condition, such as cancer, developing resistance to any single treatment. For instance, in July 2023, Merck & Co., Inc., a US-based pharmaceutical company, announced the Phase 3 KEYNOTE-756 trial evaluating KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy approved by the Food and Drug Administration, a US-based government agency. The trial met its primary endpoint by significantly improving the pathological complete response (pCR) rate in patients with high-risk, early-stage ER+/HER2- breast cancer. KEYNOTE-756 is the first positive Phase 3 trial demonstrating a statistically significant improvement in pCR rate with an immunotherapy regimen in the neoadjuvant setting for patient population. The trial assessed KEYTRUDA with chemotherapy as a neoadjuvant treatment, followed by adjuvant KEYTRUDA plus endocrine therapy for high-risk, early-stage ER+/HER2- breast cancer.
What are the key regional dynamics of the metastatic hr+/her2- breast cancer market, and which region leads in market share?
North America was the largest region in the dominated market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic HR+/HER2- breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Metastatic HR+/HER2- Breast Cancer Market Report 2025 Offer?
The metastatic hr+/her2- breast cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Metastatic HR+/HER2- breast cancer refers to a form of breast cancer where the cancer cells have spread beyond the breast to other parts of the body. Metastatic HR+/HER2- breast cancer is treated using targeted therapies, hormonal treatments, and chemotherapy to manage disease progression and improve patient outcomes.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21220
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
